Context defines precision: rethinking KRAS inhibition in oncology

Area of Science:

• Oncology
• Molecular Biology
• Translational Medicine

Background:

• Recent advances have made KRAS oncogenes targetable for therapy.
• Clinical responses to KRAS inhibitors are inconsistent across different tumor types.
• Mutation status alone is insufficient for predicting treatment outcomes.

Purpose of the Study:

• To introduce a multidimensional framework for understanding KRAS-targeted therapy.
• To integrate KRAS mutational status with other biological contexts.
• To guide rational clinical trial design and biomarker development.

Main Methods:

• Literature review and synthesis of existing data.
• Development of a conceptual framework integrating multiple data dimensions.
• Analysis of KRAS pathway signaling and tumor microenvironment interactions.

Main Results:

• A framework combining KRAS mutation, tissue type, co-mutations, signaling pathways, and immune context is proposed.
• This integrated approach offers a more comprehensive view than mutation status alone.
• The framework facilitates prediction of therapeutic response and identification of resistance mechanisms.

Conclusions:

• KRAS-targeted therapies require a multidimensional approach for optimal efficacy.
• Integrating diverse biological data can improve patient stratification and treatment strategies.
• This framework advances the development of personalized KRAS-targeted treatments.